OG1 Activators
BGLAP, encoding the protein OG1, is a key player in bone metabolism, contributing to osteoblast function and bone mineralization. While direct chemical activators for OG1 are not explicitly documented, several compounds indirectly influence OG1 through modulation of pathways associated with bone health.Calcitriol, the active form of vitamin D3, influences OG1 by binding to the vitamin D receptor (VDR). This complex translocates to the nucleus, modulating BGLAP transcription and promoting osteoblast differentiation. In a similar vein, Paricalcitol, a vitamin D analog, impacts OG1 through VDR activation, emphasizing the significance of vitamin D in bone health. Bisphosphonates like Alendronate, Ibandronate, and Zoledronic Acid indirectly influence OG1 by inhibiting farnesyl diphosphate synthase in the mevalonate pathway. This inhibition affects protein prenylation, impacting osteoblast function and BGLAP expression, highlighting their potential in bone-related disorders.
Teriparatide and Abaloparatide, recombinant parathyroid hormone analogs, stimulate osteoblast function through the PTH/PTHrP receptor, indirectly enhancing BGLAP expression and bone formation. Similarly, Romosozumab, a monoclonal antibody, indirectly activates OG1 by inhibiting sclerostin, a negative regulator of osteoblast activity. Denosumab, a monoclonal antibody, indirectly influences OG1 by inhibiting osteoclast activity through RANKL inhibition, impacting bone remodeling and BGLAP expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1α,25-Dihydroxyvitamin D3 | 32222-06-3 | sc-202877B sc-202877A sc-202877C sc-202877D sc-202877 | 50 µg 1 mg 5 mg 10 mg 100 µg | $220.00 $645.00 $1000.00 $1500.00 $440.00 | 32 | |
Calcitriol, the active form of vitamin D3, influences OG1 by binding to the vitamin D receptor (VDR). This complex translocates to the nucleus, modulating BGLAP transcription. Calcitriol's role in osteoblast differentiation and bone mineralization underscores its potential to indirectly activate OG1 through the vitamin D pathway, emphasizing its relevance in skeletal health. | ||||||
Parathyroid hormone fragment (1-34) | 52232-67-4 | sc-487943 | 100 µg | $185.00 | ||
Teriparatide, a recombinant parathyroid hormone analog, indirectly activates OG1 by stimulating osteoblast function through the PTH/PTHrP receptor. This enhances BGLAP expression and bone formation. Teriparatide's role in promoting bone health and preventing fractures underscores its significance as an indirect activator of OG1, particularly in conditions associated with bone loss. | ||||||
Strontium Ranelate | 135459-87-9 | sc-208403 | 10 mg | $320.00 | ||
Strontium Ranelate influences OG1 indirectly by enhancing osteoblast activity and inhibiting osteoclast function. This dual action impacts bone remodeling and BGLAP expression. Strontium Ranelate's role in improving bone density and reducing fracture risk highlights its potential as an OG1 activator, particularly in the context of conditions characterized by altered bone metabolism. | ||||||
Ibandronate Sodium Monohydrate | 138926-19-9 | sc-218589 | 100 mg | $290.00 | ||
Ibandronate, a bisphosphonate, indirectly influences OG1 by inhibiting farnesyl diphosphate synthase in the mevalonate pathway. This inhibition affects protein prenylation, impacting osteoblast function and BGLAP expression. The modulation of bone turnover by Ibandronate emphasizes its potential as an indirect OG1 activator, particularly in the context of bone-related disorders. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene, a selective estrogen receptor modulator, indirectly influences OG1 by binding to estrogen receptors and impacting osteoblast function. This modulates BGLAP expression and bone metabolism. Raloxifene's role in preserving bone density and reducing fracture risk underscores its potential as an OG1 activator, particularly in conditions associated with estrogen deficiency. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic Acid, a bisphosphonate, indirectly influences OG1 by inhibiting farnesyl diphosphate synthase in the mevalonate pathway. This inhibition affects protein prenylation, impacting osteoblast function and BGLAP expression. Zoledronic Acid's role in preventing bone resorption highlights its potential as an indirect OG1 activator, particularly in the context of osteoporosis and bone-related disorders. | ||||||
Paricalcitol | 131918-61-1 | sc-477938 sc-477938A | 0.5 mg 1 mg | $450.00 $550.00 | 1 | |
Paricalcitol, a vitamin D analog, indirectly influences OG1 by binding to the vitamin D receptor (VDR). This complex translocates to the nucleus, modulating BGLAP transcription. Paricalcitol's role in regulating bone metabolism and enhancing osteoblast function emphasizes its potential as an indirect OG1 activator, particularly in conditions associated with vitamin D deficiency. | ||||||
Edoxaban | 480449-70-5 | sc-483508 | 25 mg | $522.00 | ||
Edoxaban, a factor Xa inhibitor, indirectly influences OG1 by modulating the coagulation cascade. This impacts vascular calcification and indirectly affects BGLAP expression. Edoxaban's role in potentially influencing bone metabolism underscores its unique connection to OG1, offering insights into the interplay between coagulation factors and bone-related processes. | ||||||